FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078199515> ?p ?o ?g. }

• W2078199515 endingPage "3707" @default.
• W2078199515 startingPage "3700" @default.
• W2078199515 abstract "Context: Previous randomized trials have suggested an association between radioiodine treatment for Graves’ hyperthyroidism and thyroid-associated ophthalmopathy (TAO). Objectives: The aim of the study was to compare the occurrence of worsening or development of TAO in patients who were treated with radioiodine or antithyroid drugs. Design: We conducted a randomized trial (TT 96) with a follow-up of 4 yr. Patients, Setting, and Intervention: Patients with a recent diagnosis of Graves’ hyperthyroidism were randomized to treatment with iodine-131 (163 patients) or 18 months of medical treatment (150 patients). Early substitution with T4 was given in both groups. Main Outcome Measure: Worsening or development of TAO was significantly more common in the iodine-131 treatment group (63 patients; 38.7%) compared with the medical treatment group (32 patients; 21.3%) (P < 0.001). Results: The risk for de novo development of TAO was greater in patients treated with iodine-131 (53 patients) than with medical treatment (23 patients). However, worsening of TAO in the 41 patients who had ophthalmopathy already before the start of treatment was not more common in the radioiodine group (10 patients) than in the medical group (nine patients). Smoking was shown to influence the risk of worsening or development of TAO, and smokers treated with radioiodine had the overall highest risk for TAO. However, in the group of smokers, worsening or development of TAO was not significantly associated with the choice of treatment for hyperthyroidism. Conclusions: Radioiodine treatment is a significant risk factor for development of TAO in Graves’ hyperthyroidism. Smokers run the highest risk for worsening or development of TAO irrespective of treatment modality. Radioiodine treatment for Graves’ hyperthyroidism (when compared to anti-thyroid drug treatment),and smoking increase the risk for the development of thyroid associated ophthalmopathy." @default.
• W2078199515 created "2016-06-24" @default.
• W2078199515 creator A5000874946 @default.
• W2078199515 creator A5022593811 @default.
• W2078199515 creator A5026734949 @default.
• W2078199515 creator A5043328069 @default.
• W2078199515 creator A5047082584 @default.
• W2078199515 creator A5050666144 @default.
• W2078199515 creator A5058980506 @default.
• W2078199515 creator A5059560084 @default.
• W2078199515 creator A5059907676 @default.
• W2078199515 creator A5065824777 @default.
• W2078199515 creator A5068453779 @default.
• W2078199515 creator A5072328054 @default.
• W2078199515 creator A5076735824 @default.
• W2078199515 creator A5078082518 @default.
• W2078199515 creator A5079885401 @default.
• W2078199515 creator A5082564504 @default.
• W2078199515 date "2009-10-01" @default.
• W2078199515 modified "2023-10-18" @default.
• W2078199515 title "Thyroid-Associated Ophthalmopathy after Treatment for Graves’ Hyperthyroidism with Antithyroid Drugs or Iodine-131" @default.
• W2078199515 cites W1930521840 @default.
• W2078199515 cites W1974372293 @default.
• W2078199515 cites W1982141055 @default.
• W2078199515 cites W2017184687 @default.
• W2078199515 cites W2024010187 @default.
• W2078199515 cites W2025606345 @default.
• W2078199515 cites W2031738356 @default.
• W2078199515 cites W2046575767 @default.
• W2078199515 cites W2051724008 @default.
• W2078199515 cites W2063823126 @default.
• W2078199515 cites W2066202982 @default.
• W2078199515 cites W2083863071 @default.
• W2078199515 cites W2105978282 @default.
• W2078199515 cites W2109007966 @default.
• W2078199515 cites W2128222543 @default.
• W2078199515 cites W2142291461 @default.
• W2078199515 cites W2153640804 @default.
• W2078199515 cites W2161176285 @default.
• W2078199515 cites W2167654441 @default.
• W2078199515 cites W2320293007 @default.
• W2078199515 cites W2337157164 @default.
• W2078199515 cites W2342151268 @default.
• W2078199515 doi "https://doi.org/10.1210/jc.2009-0747" @default.
• W2078199515 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19723755" @default.
• W2078199515 hasPublicationYear "2009" @default.
• W2078199515 type Work @default.
• W2078199515 sameAs 2078199515 @default.
• W2078199515 citedByCount "209" @default.
• W2078199515 countsByYear W20781995152012 @default.
• W2078199515 countsByYear W20781995152013 @default.
• W2078199515 countsByYear W20781995152014 @default.
• W2078199515 countsByYear W20781995152015 @default.
• W2078199515 countsByYear W20781995152016 @default.
• W2078199515 countsByYear W20781995152017 @default.
• W2078199515 countsByYear W20781995152018 @default.
• W2078199515 countsByYear W20781995152019 @default.
• W2078199515 countsByYear W20781995152020 @default.
• W2078199515 countsByYear W20781995152021 @default.
• W2078199515 countsByYear W20781995152022 @default.
• W2078199515 countsByYear W20781995152023 @default.
• W2078199515 crossrefType "journal-article" @default.
• W2078199515 hasAuthorship W2078199515A5000874946 @default.
• W2078199515 hasAuthorship W2078199515A5022593811 @default.
• W2078199515 hasAuthorship W2078199515A5026734949 @default.
• W2078199515 hasAuthorship W2078199515A5043328069 @default.
• W2078199515 hasAuthorship W2078199515A5047082584 @default.
• W2078199515 hasAuthorship W2078199515A5050666144 @default.
• W2078199515 hasAuthorship W2078199515A5058980506 @default.
• W2078199515 hasAuthorship W2078199515A5059560084 @default.
• W2078199515 hasAuthorship W2078199515A5059907676 @default.
• W2078199515 hasAuthorship W2078199515A5065824777 @default.
• W2078199515 hasAuthorship W2078199515A5068453779 @default.
• W2078199515 hasAuthorship W2078199515A5072328054 @default.
• W2078199515 hasAuthorship W2078199515A5076735824 @default.
• W2078199515 hasAuthorship W2078199515A5078082518 @default.
• W2078199515 hasAuthorship W2078199515A5079885401 @default.
• W2078199515 hasAuthorship W2078199515A5082564504 @default.
• W2078199515 hasBestOaLocation W20781995151 @default.
• W2078199515 hasConcept C126322002 @default.
• W2078199515 hasConcept C134018914 @default.
• W2078199515 hasConcept C151730666 @default.
• W2078199515 hasConcept C168563851 @default.
• W2078199515 hasConcept C191897082 @default.
• W2078199515 hasConcept C192562407 @default.
• W2078199515 hasConcept C2776606491 @default.
• W2078199515 hasConcept C2776652619 @default.
• W2078199515 hasConcept C2776685619 @default.
• W2078199515 hasConcept C2779343474 @default.
• W2078199515 hasConcept C2909564963 @default.
• W2078199515 hasConcept C526584372 @default.
• W2078199515 hasConcept C539932907 @default.
• W2078199515 hasConcept C71924100 @default.
• W2078199515 hasConcept C86803240 @default.
• W2078199515 hasConceptScore W2078199515C126322002 @default.
• W2078199515 hasConceptScore W2078199515C134018914 @default.
• W2078199515 hasConceptScore W2078199515C151730666 @default.
• W2078199515 hasConceptScore W2078199515C168563851 @default.

• next